Non-Hodgkin Lymphoma | Specialty

The Phase II EZH2 Inhibitor Trial

January 28th 2020

Sequencing Strategies for Later-Line Therapy

January 28th 2020

The DYNAMO Later-Line Regimen

January 28th 2020

Treatment Options After Second-Line Relapse

January 28th 2020

Relapsed/Refractory Treatment: The MAGNIFY Regimen

January 28th 2020

Determining Second-Line Therapy in FL

January 28th 2020

Phase III GALLIUM Results and Maintenance Therapy

January 28th 2020

Immunochemotherapy Decision Factors

January 28th 2020

When to Initiate Therapy for Follicular Lymphoma

January 28th 2020

The Importance of Risk Assessment

January 28th 2020

Differential Diagnosis and Staging of Follicular Lymphoma

January 28th 2020

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

January 27th 2020

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Dr. Kaplan on Frontline Treatment Options in Follicular Lymphoma

January 18th 2020

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

Novel Agents Strengthen Treatment Armamentarium in Non-Hodgkin Lymphoma

January 3rd 2020

Parameswaran Venugopal, MD, discusses current and emerging treatment strategies in non-Hodgkin lymphoma.

Dr. Noy on the Rationale to Evaluate Devimistat in Burkitt Lymphoma

December 19th 2019

Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.

Bispecific Antibody Shows High Clinical Activity in Heavily Pretreated NHL

December 11th 2019

REGN1979 demonstrated antitumor activity with an acceptable safety profile in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Triplet Regimen Induces High Rate of CR in R/R Follicular Lymphoma

December 8th 2019

The combination of polatuzumab-vedotin (Polivy), obinutuzumab (Gazyva), and lenalidomide (Revlimid) induced a high rate of durable responses in patients with relapsed/refractory follicular lymphoma.

New Sequencing Approaches Shape Follicular Lymphoma Landscape

November 6th 2019

With a variety of available agents in follicular lymphoma, determining which treatments to choose and how best to sequence them can be challenging.

Personalized, Chemo-Free Regimens Emerging in Follicular Lymphoma

October 9th 2019

Kieron Dunleavy, MD, discusses emerging treatment options and when to use the watch-and-wait approach in follicular lymphoma.

Dr. Westin on Response Rates in the JULIET Trial for DLBCL

September 14th 2019

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.